INTRODUCTION
It may fairly be claimed that up to the last decade no antiepileptic drug (AED) had undergone rigorous testing. Coatsworth I in a comprehensive review of AED assessment reported three controlled trials up to 1971, and Richens (1976) was able to identify some 17. Gram and coworkers found 51 by 1982, but the majority suffered gross methodological deficiencies. In the past decade the situation has changed dramatically, the number of controlled AED trials currently in progress must exceed the total of those completed before 1983. The development programmes of the new AEDs registered in recent years have necessarily been innovative, and methods of AED testing are still undergoing rapid evolutionary change. Conventional phase II AED trials are usually placebo controlled studies employing designs of either single period parallel groups or multiple periods within patients. Since it is, in general, unacceptable to withhold effective treatment from a patient with epilepsy, during conventional AED trials the experimental drug is added to the presumably partially effective medication already being taken (add-on trials). Although widely regarded as an ethical necessity, this approach poses a number of problems which often makes this design difficult to interpret: (1) Drug interactions may confound both therapeutic and adverse effects. Elevation of blood levels of comedication may cause intoxication, which may be wrongly attributed to the experimental agent 4"5 and efficacy can be wrongly ascribed to a new product because it causes an increase in concentrations of comedication 6. Conversely increased clearance of the comedication may reduce apparent efficacy. (2) Induction of metabolism by the comedication may produce lower than expected blood levels and result in a failure to demonstrate any effect of the experimental drug. (3) Efficacy and adverse events may depend on a pharmacodynamic synergy with the comedication.
A number of alternative trial designs are now available and increasing attention has recently been directed to ethically acceptable monotherapy designs 7. One approach, first adopted by Bourgois et al 8, in the development of Felbamate, is the performance of monotherapy trials in patients whose AEDs had been withdrawn to facilitate capture of seizures by telemetry, as part of a preoperative assessment protocol. The conduct of such trials is difficult and complex. The patients are in an unstable state and there may be only a brief interval between capturing sufficient seizures to meet the needs of preoperative assessment and the onset of serial seizures demanding immediate control. To be of demonstrable efficacy under these circumstances, the test drug must act swiftly. If the onset of drug action is delayed by one or two days, the opportunity to prove an effect may be missed. This may happen if the half life is long or efficacy depends on an active metabolite or if there are constraints on the rate of dose escalation. In many patients, it is impossible to achieve monotherapy if seizure frequency increases rapidly before existing medication is fully withdrawn 8.
We report two variants of this design: an open trial of remacemide hydrochloride (Fisons CR 2083), and a controlled trial of tiagabine (Abbott M90-511 TIA-102) in which the test treatment was introduced prior to withdrawal of other medication. This last approach may avoid many of the difficulties described above, but will prolong the period of telemetry in patients who respond to the active treatment. For reasons which will be apparent, both were inconclusive but they are reported here as illustrating some of the methodological possibilities and problems of this novel type of trial design.
REMACEMIDE HYDROCHLORIDE TRIAL The drug
When administered orally in rodents, remacemide hydrochloride protects against maximal electroshock induced seizures with a potency similar to that of phenytoin, phenobarbitone or carbamazepine and greater than valproate. It is also effective against absence-like seizures in rats 9. The desglycinyl derivative of remacemide is an active metabolite in the rat and has also been identified in the dog and man m'~l. In healthy volunteers the drug has been generally well tolerated at single doses of up to 400mg or at 150 mg q.i.d, for six days. Minor adverse events (gastrointestinal upset, nausea and lightheadedness) were observed at higher doses. The mechanism of action of remacemide hydrochIoride has not been fully elucidated but it appears to differ from that of other AEDs. The compound has been shown to enhance the survival of mice in a hypoxic environment and to exert a neuroprotective effect against global and focal cerebral ischaemia in rodents and higher species 12.
Patients
Ten male patients aged between 19-41 years (average, 25.7) entered the study. Table 1 summarizes the demographic and pretreatment 
Phase B

Study design
After a pre-study screening and seizure documentation over at least four weeks, the withdrawal of AEDs and presurgical EEG telemetry, eligible patients received remacemide hydrochloride 150mg q.i.d, for a maximum of 28 days. The study treatment was administered initially as monotherapy but in some patients continuing seizures required the reinstitution of their standard antiepileptic drugs. The study was carried out in two phases: Phase A (first five days) and Phase B (6 to 28 days).
Phase A
Patients satisfying the study entry criteria received remacemide hydrochloride, as above.
Phase B was the continuation of the studv from the end of Dav 5 (i.e. Phase A) to dav 28. Only patients completing all 5 days of Phase A were to be considered for Phase B. During Phase B patients were discharged home but were to be evaluated on at least four occasions. The patient kept a daily record of seizure frequency and type, adverse events, and concomitant medications throughout this phase. During Phase B, patients would be on remacemide hydrochloride monotherapy, or on remacemide hydrochloride plus standard AED comedication, or on remacemide hvdrochloride monotherapy at day 6, followed by addition of standard AED at any point during Phase B. Remacemide hydrochloride was reduced gradually over four days at the end of phase B in order to reduce the risk of withdrawal seizures. 
Results
Efficacy
Seizure frequency was recorded at baseline and throughout the study period up to and including day 5 (Table 2 ). Additional data after this time were available only for patient 5, who completed Phase B of the study. Seizure frequency for this patient did not appear to alter significantly during this phase. Total seizure frequency on days 1 and 2 ~vere compared with baseline (day -1) using a Wilcoxon Matched Pairs Signed Rank test. Statistical analysis of data on days 3, 4 and 5 was not possible due to insufficient sample size (caused by patient withdrawals). A total of nine patients were included in an analysis of total seizure frequency, which compared day 1 of the study with baseline (day -1) and a total of seven patients were included in an analysis of total seizure frequency which compared day 2 of the study with baseline (day -1). Although a reduction of median seizure frequency was seen on days 1 and 2 when compared with baseline, this difference did not achieve statistical significance. Analysis of complex partial seizure frequency and secondarily generalized seizure frequency also showed no statistically significant differences between the two study days and baseline. It was not possible to analyse simple partial and generalized seizure frequencies due to insufficient data.
Safety
Of the 10 patients who received remacemide hydrochloride, only one patient received the drug for the complete study period of 28 days. The remainder stopped study treatment between one and five days after the start of dosing, due to adverse events or deterioration of epilepsy (Table  3) . Nine patients experienced adverse events during the study. Six patients experienced events during the baseline period, seven during Phase A of the treatment period, one patient during Phase B and one patient during the follow-up period.
The most commonly experienced event during the treatment period was headache (three patients). No serious events were reported during the study. Seven patients experienced events which were thought to be possibly related to test treatment and included myalgia, malaise and dizziness, hyperaesthesia, vomiting, confusion, hypoaesthesia, nausea, anxiety, paraesthesia and hyperventilation, and abnormal vision.
TIAGABINE TRIAL The drug
Tiagabine hydrochloride (HCI) is a potent and specific inhibitor of GABA uptake by glial and neuronal elements in vitro. Following administration by intraperitoneal injection it has potent anticonvulsant activity in animal models. In volunteers, adverse events can be observed at doses above 12 mg/day, including dizziness, headache, somnolence, abnormal vision, poor concentration, incoordination, stupor, confusion or nausea 13.
human chorionic gonadotrophin pregnacy test at day -1. Patients taking primidone or phenobarbital had this medication discontinued prior to admission to the study. The plasma phenobarbital concentration was required to be -< 10/zg/ml prior to day -
Patients
Eleven patients entered the study with ages between 17 and 52 (mean, 32.8) years. The mean age for the patients in the tiagabine HCL and in the placebo group was 38.3 and 23.3 years, respectively. Patient characteristics are shown in Table 4 . Patients were capable of signing an informed consent, were hospitalized during the double-blind and washout phases, and had a diagnosis of epilepsy with complex partial seizures supported by observed ictal events documented by reliable witnesses and confirmed by at least one of the following: (1) ictal electroencephalogram (EEG), (2) interictal EEG demonstrating epileptiform activity, (3) computed tomography or magnetic resonance imaging showing a focal cerebral lesion consistent with complex partial seizures. Additional requirements in female patients were at least one of the following: (1) being surgically sterilized, (2) at least one year postmenopausal, (3) an intrauterine device in place for at least one month, (4) use of an oral contraceptive for at least one menstrual cycle, and for the duration of the study; (5) a negative
Study design
The study consisted of an open phase (28 days), a double-blind treatment phase (seven days) and a washout phase (24 hours). During the screening visit of the open phase, patients provided written informed consent and a medical history, underwent a physical examination and laboratory tests. Within four weeks following the Screening Visit, eligible patients were admitted to the hospital, where they remained for the duration of the study. On day -1 of the open phase (the day before starting the double-blind treatment phase), an interval medical and seizure history, and laboratory tests were obtained. During the seven-day double-blind phase, randomized patients were dosed every four hours with the tiagabine HCI or matching placebo. Assignment to the treatment group was balanced (1:1) between placebo and tiagabine HC1. Patients had their dose of study treatment titrated by a physician blinded to medication to achieve either the maximum well tolerated dose or 66 mg/day (or equivalent number of placebo capsules). Concomitant AEDs were discontinued with start 
Results
Eleven patients were enrolled, seven received tiagabine HCI and four received placebo. Three patients completed the study.
Premature discontinuation
Eight patients were prematurely discontinued from the study. Five patients were discontinued because the number of seizures exceeded the escape criteria. Two patients (one on Tiagabine and one on placebo) experienced three convulsive seizures within 24 hours. Two patients (on placebo) experienced two convulsive seizures within three hours. One patient (on Tiagabine) experienced more than seven seizures in a 48 hour period with a baseline rate of 0.32 seizures/day. One patient (on placebo) was discontinued because of protocol violation (not keeping a seizure diary during the open phase). Two patients (on Tiagabine) were discontinued because of an adverse event.
Drug administration
Tiagabine or placebo were administered approximately every four hours on the dosing days. Of the patients on tiagabine HCI, only two were administered the maximum study drug dose of 66 mg/day, both of whom successfully completed the study. Four other patients received maximum study drug doses of 42 mg/day, 41 mg/day, 28 mg/day and 25 mg/day. All patients stopped all marketed antiepilepsy drugs (AEDs) on or prior to day 1 except for one patient who took vigabatrin thoughout the study.
Efficacy
While the sample size was too small for statistical significance to be attained, the results suggest efficacy of tiagabine HCi for complex partial, simple partial, combined partial and secondarily generalized tonic-clonic seizures because the patients in the tiagabine HCI group experienced fewer seizures than the placebo group in the double-blind period. Based on median seizure rates, there was no seizure type in either group that lessened in frequency during the doubleblind period but the tiagabine HCI group had less increase in seizures of all types ( 
Secondarily generalised tonic-clonic seizures.
During the open phase, tiagabine HCl-treated patients experienced 0.143 more seizures per 24 hours than patients on placebo. During the double-blind phase, tiagabine HCl-treated patients had a median of 0.869 fewer seizures per 24 hours than patients on placebo. 
Safety
Nine patients (82%) experienced at least one treatment-emergent adverse event. The most frequent adverse events were related to the nervous system (Table 6 ). At least one treatmentemergent adverse event was reported by 7/7 (100%) patients receiving tiagabine HCl and by 2/4 (50%) patients receiving placebo. All adverse events were considered to be mild to moderate in severity. Ten patients reported headache and nine patients reported cheek pain on day -1. These were attributed to the insertion of foramen ovale electrodes. Two of the 11 patients (18%) were prematurely discontinued during the study because of adverse events. Both patients had been on tiagabine HC1. One patient was discontinued because of moderate nausea on day 3 and another patient was discontinued because of moderate depression on day 5 and withdrawn consent.
DISCUSSION
Conventional double-blind add-on trials can be expected to show little difference between placebo and novel drugs unless the latter are significantly more effective than the existing standard treatment j4. While a difference greater than 50% is regarded as indicative of effectiveness in most add-on trials, this outcome is unlikely even if the tested drug is known to be effective, as shown by Schmidt 15 who found an improvement in only 15% of patients when a second marketed drug was added to the regime.
Monotherapy trials during presurgical assessment are potentially a good alternative to complement add-on studies both to establish efficacy and to justify early initiation of more conventional monotherapy trials. Pharmacological interactions are avoided and since no other therapeutic agents are simultaneously present, there is not a basal seizure control over which the new agent has to demonstrate further efficacy. This implies that agents which are at least as active and effective in the same patients as already marketed drugs can in principle show an effect. There are however a number of problems, both theoretical and practical, that complicate the interpretation and conduct of monotherapy trials during preoperative assessment.
Sudden withdrawal of antiepileptic medication can be associated with an increase in the incidence of seizures ~6 and it is in general not clear the extent to which this might be due to halting effective therapy or to rebound withdrawal effects. The influence of withdrawal seizures on results can be minimized by using parallel placebo controlled designs. Although the absolute incidence of seizures on the test drug can exceed baseline values after withdrawal of standard antiepileptic medication, even if the novel drug is effective, such increment would be expected to be higher in patients on placebo. Indeed we found that seizure frequency increased during tiagabine treatment after withdrawal of standard antiepileptic medication but the increment was higher in patients on placebo for all seizure types, which suggests that tiagabine possesses a degree of effectiveness although the small number precluded formal statistical analysis. No such conclusion would have been possible if tiagabine had been tested on an open-label basis, as in the case of remacemide hydrochloride. Consequently., no comparisons can be drawn between the relative efficacy of tiagabine and remacemide hydrochloride since the study designs were disimilar. Whether suppression of withdrawal seizures is predictive of efficacy in epilepsy may be disputed. An alternative approach which avoids this last problem would be to randomize patients and start experimental treatment whilst gradually tapering off standard antiepileptic medication during several days before surgical assessment. Phenobarbitone, whether adminstered as such or arising as a metabolite of primidone, has a long half life (24-48 hours) and primidone administration was consequently stopped between 48 and 72 hours before day 1.
Monotherapy trials during presurgical assessment allow only a short time available to show therapeutic effects. This is an important limitation since absolute seizure frequency can increase during the trial even if the novel drug is effective and in this situation it is difficult for the blinded physician to justify continuing the trial. Objective escape criteria must be applied to ensure withdrawal of patients at risk of harm from continuing in the trial (see Material and Methods of Tiagabine trial). These criteria should be pragmatic and take account of the hazards associated with different types of seizure and of the patients' habitual seizure type and severity.
As with add-on trials, presurgical monotherapy trials will include patients with particularly refractory epilepsy. If a drug does not show efficacy in presurgical patients it could still be effective in other milder epilepsy. Both tiagabine HCI and remacemide HC1 have proven efficiency in traditional design trials ~°'7"18.
Experiencing a greater than usual seizure frequency over a short period of time is necessarily disagreeable. Moreover, in many centres invasive procedures are often used during presurgical assessment. These factors combine to give rise to adverse events which can be difficult to distinguish from those induced by the novel drug. For instance most of our patients had undergone implantation of foramen ovale electrodes under general anaesthesia which is often associated with headache, nausea and facial pain lasting for several days, and often overlapped with trial day 1. Headache is often of several days duration and was thus indistinguishable from headaches possibly induced by the experimental drug. Some other adverse events are more likely to be drug specific (drowsiness, tremor, ataxia) and can be appropriately monitored to study drug safety during monotherapy trials. The pressure of time creates the need to escalate the dose of the experimental dose faster than would be normal practice; this may lead to an incidence of drug-induced adverse experiences greater than would be encountered with routine use. This problem would be alleviated by introducing the study treatments more gradually prior to withdrawal of comedication.
Sample size in monotherapy trials during surgical assessment will in general be smaller than in more conventional trials. This means that seizure reduction would have to be greater in order to achieve statistical significance. For instance, in order to obtain an 80% chance of finding existing differences at a 5% significance level, seizure reduction will have to be 0.78 times the standard deviation for a 10 patient sample, whereas it would have to be 0.25 for 100 patients and 0.18 for 200 patients.
In summary, monotherapy trials during presurgical assessment offer a relatively new methodology to study efficacy and safety of antiepileptic drugs during Phase II with minimal interactions with standard anticonvulsants. Placebo controlled parallel double blind designs are preferable because absolute seizure frequency can increase during the trial due to withdrawal seizures, even if the novel drug is effective. A number of difficulties outlined above could largely be overcome by gradually introducing and possibly titrating to the tolerated limits the experimental treatments prior to withdrawal of comedication and tapering off standard antiepileptic medication over several days before surgical assessment. With an effective treatment, patients randomized to the active compound at therapeutic doses should show no, or less, withdrawal seizures. Anticonvulsant pharmacokinetics should be carefully considered and the timing of withdrawal of standard anticonvulsants planned so that subtherapeutic levels are not reached before surgical assessment in patients on placebo. If the novel drug is effective, admission time and duration of invasive recordings would be lengthened but this would be amply justified if some patients were controlled on the experimental agent and therefore avoided surgery.
